NEW YORK—The first clinical trials of a live genetically engineered Salmonella typhimurium bacterium are expected to get underway in the second half of this year in patients with cutaneous metastases of melanoma and breast cancer.
Terrence W. Doyle, PhD, vice president for research and development, Vion Pharmaceuticals, Inc., New Haven, Connecticut, revealed plans for the phase I study at Current Concepts in Cancer Therapy II, a scientific symposium sponsored by Long Ridge Associates. Developed in his company’s proprietary program, Tumor Amplified Protein Expression Therapy (TAPET), the bacterium, VNP20009, will be injected directly into the skin lesions in the initial trial.
The aim of the study will be to determine the agent’s safety and appropriate dose range in humans. “We’re looking for the minimum effective inoculum,” Dr. Doyle said. “Unlike many antitumor agents, because this is a multiplying vector, we don’t have any need to try to reach a maximum tolerated dose, and it is far better to just simply find the dose where we can get uniform colonization.”
Animal studies have shown that the bacteria preferentially target tumors over normal tissue by more than 1000:1, Dr. Doyle said. An important difference from other therapeutic modalities, he added, is that the motile organism penetrates all compartments of the tumor, including the hypoxic and necrotic layers.
In contrast to wild type salmonella, VNP20009 produced no septic shock in swine and no changes in the body temperature of cynomologus monkeys. Tests of antibiotic sensitivity showed that “if anything, it was more sensitive than the wild strain,” Dr. Doyle commented.
Ultimately, Vion researchers expect TAPET to deliver recombinant genes or other toxic payloads to solid tumor, but, in research, VNP20009 alone achieved 95% suppression of B16 melanoma in mice, a level slightly better than that seen with optimal doses of fluorouracil(Drug information on fluorouracil) and cyclophosphamide(Drug information on cyclophosphamide).
Human Colon Cancer Model
In a model of human colon carcinoma DLD-1 in mice, VNP20009 was injected on day 17 after tumor implantation, when the median tumor volume was 300 mm². With the agent, “we’re able to stop the tumor growth cold,” Dr. Doyle said, “whereas the control animals progressed rather quickly to death.”
In research leading up to clinical trials, B16 melanoma was implanted into both flanks of mice. Five days later, B16 tumor cells were injected into the tail vein causing implantation in the lungs. Without treatment, the mice die at day 21 or 22 from growth of the flank tumors. “Injection of VNP20009 into one of these tumors induces excellent inhibition of that tumor,” Dr. Doyle said, and “a little less good inhibition of the contralateral tumor as well as inhibition of the lung mets.” When VNP20009 was injected into the tail vein, both the laterally implanted tumors and the lung mets were equally suppressed (see figure).
Based on these findings, the company hopes to move to a phase I study of IV administration.
